Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
暂无分享，去创建一个
B. Becher | M. Boerries | M. Punta | J. Duyster | S. Unger | R. Wäsch | B. Gentner | G. Ihorst | L. Vago | R. Zeiser | G. Andrieux | H. Bertz | R. Marks | D. Pfeifer | S. Kreutmair | Theresa Lowinus | P. Apostolova | Sandra Duquesne | C. Wehr | W. Melchinger | K. Shoumariyeh | Laura Power | Chiara Alberti | Eliza M. Lauer | C. Toffalori | Rouven Hoefflin | Nicolás Gonzalo Núñez | C. Alberti | Juergen A. Finke | C. Merten | Matthias Weiss | Valerie Hupfer | E. Haring | Kristina Maas-Bauer | Ann-Cathrin Burk | Sara da Costa Pereira | Caroline Böke | Claudia Wehr | Cristina Toffalori | J. Finke